Pharmacological approaches to the treatment of obstructive sleep apnoea

@article{Kohler2009PharmacologicalAT,
  title={Pharmacological approaches to the treatment of obstructive sleep apnoea},
  author={M. Kohler and K. Bloch and J. Stradling},
  journal={Expert Opinion on Investigational Drugs},
  year={2009},
  volume={18},
  pages={647 - 656}
}
Background: Currently the treatment of choice for symptomatic obstructive sleep apnoea (OSA) is continuous positive airway pressure (CPAP). Some patients with OSA do not tolerate CPAP or have insufficiently severe symptoms to justify its use; for these patients, drug therapy would be a desirable potential therapeutic alternative. Objective: To summarize the current evidence on the effectiveness of drug therapy in patients with OSA. Methods: A systematic review of randomized controlled trials… Expand
Pitfalls of clinical trials on pharmacological treatment for obstructive sleep apnoea: future directions
TLDR
The pitfalls of clinical trials on pharmacological OSA therapy are summarised and potential solutions and directions for future studies are given. Expand
Adjunctive Therapy to CPAP: Sedative Hypnotics, Heated Humidification, and Supplemental Oxygen
TLDR
Adjunctive measures that may help increase adherence to therapy among patients with OSA and the use of supplemental oxygen when conditions warrant its use are examined. Expand
Pharmacologic approaches for the management of symptoms and cardiovascular consequences of obstructive sleep apnea in adults
TLDR
Preliminary studies suggest that inhibition of the enzyme xanthine oxidase and inhibition of sympathetic nervous system overactivity may have therapeutic potential to reduce cardiovascular harm in patients with OSA. Expand
Adjunctive and Alternative Therapies for Obstructive Sleep Apnea
TLDR
Upon initial visit, it is important to screen for hypothyroidism, acromegaly, and nasal obstruction, and to assess the risk of drowsy driving and impaired performance at school or work. Expand
CPAP treatment in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea—therapeutic difficulties and dilemmas
TLDR
The initial results of Greek Sleep Center’s participation in this project show multiple problems related to specific characteristics of IPF patients with OSA, and whether currently available OSA therapy with CPAP can be applied and whether it can improve not only OSA-related daytime symptoms and overall quality of life, but also disease-related morbidity and mortality. Expand
Drug Trials for Obstructive Sleep Apnea Commentary on Larrain et al. Pharmacological Treatment of Obstructive Sleep Apnea with a Combination of Pseudoephedrine and Domperidone. J Clin Sleep Med 2010;6:117-123.
TLDR
ffective drugs for primary treatment or prevention of ob-structive sleep apnea in adult patients would be a paradigm shift for the field, and alter-natives to these mechanical and structural approaches would expand the management horizon. Expand
Drug effects on ventilatory control and upper airway physiology related to sleep apnea
TLDR
A review of human studies that contain both drug effects on sleep-disordered breathing and measures of ventilatory control or upper airway physiology and the presence of paradoxical findings highlights the complexity of drug therapy for OSA. Expand
Mechanisms of vascular damage in obstructive sleep apnea
TLDR
More clinical interventional trials are needed to determine the magnitude of the effect OSA has on cardiovascular damage and to enable a comparison with conventional vascular risk factors. Expand
Recent advances in obstructive sleep apnea pathophysiology and treatment
TLDR
The promise of phenotyping patients according to their individual pathophysiology in order to target one or more therapies may prove highly effective and allow the treatment of OSA towards a personalized medicine approach. Expand
Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs.
TLDR
Topical administration of AVE0118 to the UA is a promising pharmacologic approach for the treatment of OSA and is moderately effective in line with reported clinical efficacy. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 93 REFERENCES
Drug therapy for obstructive sleep apnoea in adults.
TLDR
The use of drug therapy in the treatment of OSA was proposed as an alternative to CPAP in some patients with mild to moderate sleep apnoea and could be of value in patients intolerant of CPAP and many trials had methodological limitations. Expand
Pharmacological treatment of sleep apnea: current situation and future strategies.
TLDR
Future pharmacological treatments for OSA may need to take aspects other than the nocturnal breathing events alone into consideration, and some potential shortcomings and possibilities of pharmacological treatment in OSA are listed. Expand
Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis.
TLDR
Intranasal fluticasone is of benefit to some patients with OSAS and rhinitis and the data suggest that this form of nasal obstruction may contribute to the pathophysiology of OSAS. Expand
Obstructive Sleep Apnea and Hypopnea Efficacy and Safety of a Long-Acting beta2-Agonist.
TLDR
In patients with OSAS, salmeterol had no adverse effect on quality of sleep, AI or AHI, and turned out to be safe in terms of OSAS. Expand
Obstructive Sleep Apnea and Hypopnea Efficacy and Safety of a Long-Acting β2-Agonist
TLDR
In patients with OSAS, salmeterol had no adverse effect on quality of sleep, AI or AHI, and turned out to be safe in terms of OSAS. Expand
Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/hypopnoea syndrome
TLDR
Objectively monitored CPAP use averaged only 3.4 (0.4) hours per night, but this study provides evidence of improved cognitive performance even at this low level of CPAP compliance. Expand
CPAP and measures of cardiovascular risk in males with OSAS
TLDR
Treatment of obstructive sleep apnoea with continuous positive airway pressure may lower cardiovascular risk by reducing sympathetic nerve activity, ambulatory blood pressure and arterial stiffness and by increasing sensitivity of the arterial baroreflex. Expand
Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome.
TLDR
It is concluded that protriptyline may have a limited role in the treatment of the sleep apnea syndrome and acetazolamide produced a physiological, but not a symptomatic, response. Expand
Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea.
TLDR
It is concluded that enhanced serotonergic transmission improves breathing during NREM sleep in OSA, and this effect is poorly related to effects on sleep architecture or daytime symptoms. Expand
Efficacy of mirtazapine in obstructive sleep apnea syndrome.
TLDR
The findings suggest the therapeutic potential of mixed-profile serotonergic drugs in OSA and provide support for future studies with related formulations, but do not recommend use of mirtazapine as a treatment for OSA. Expand
...
1
2
3
4
5
...